Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2010

01.10.2010 | Original Article

Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine

verfasst von: Hironori Iwasaki, Takafumi Okabe, Kensaku Takara, Yasuhiko Yoshida, Kaoru Hanashiro, Hirosuke Oku

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nitidine (NTD) cytotoxicity is highly specific for A549 human lung adenocarcinoma cells. We hypothesized that this cytotoxicity involved the accumulation of NTD in intracellular organelles. However, there have been no reports of NTD transporting factors. In this study, we screened for an NTD transporter and evaluated its association with NTD cytotoxicity.

Methods

Gene expression analyses were done for A549 and human fetal lung normal diploid fibroblast (WI-38) cells. We screened for ABC transporter, multi-drug resistance-associated genes. Gene expressions of ATP-binding cassette transporter A1 (ABCA1) were confirmed in 8 cell lines by quantitative PCR. The involvement of ABCA1 in NTD cytotoxicity was evaluated using siRNA-mediated ABCA1 gene silencing.

Results

Gene expression analysis indicated that A549 cells expressed higher levels of ABCC1, ABCC2, ABCC3, and ABCG2 and a lower level of ABCA1 compared to WI-38 cells. NTD resistant cell lines uniformly showed higher ABCA1 expression levels. Gene silencing experiments showed that the down-regulation of ABCA1 resulted in increased sensitivity to NTD.

Conclusions

These results indicated that NTD efflux is controlled by ABCA1 activity, suggesting that ABCA1 transports molecules other than lipids. Thus, there is a possibility that ABCA1 acts as a drug resistance transporter involved in the cytotoxicity of NTD derivatives. This also suggested that the expression level of the ABCA1 gene may be an indicator for the efficiency of NTD treatment.
Literatur
1.
Zurück zum Zitat Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, Liu LF (1996) Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56:2795–2800PubMed Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, Liu LF (1996) Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56:2795–2800PubMed
2.
Zurück zum Zitat Wang LK, Johnson RK, Hecht SM (1993) Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 6:813–818CrossRefPubMed Wang LK, Johnson RK, Hecht SM (1993) Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 6:813–818CrossRefPubMed
3.
Zurück zum Zitat Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534–1541CrossRefPubMed Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534–1541CrossRefPubMed
4.
Zurück zum Zitat Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722–1726PubMed Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722–1726PubMed
5.
Zurück zum Zitat Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878PubMed Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878PubMed
6.
Zurück zum Zitat Holden JA, Wall ME, Wani MC, Manikumar G (1999) Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Arch Biochem Biophys 370:66–76CrossRefPubMed Holden JA, Wall ME, Wani MC, Manikumar G (1999) Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Arch Biochem Biophys 370:66–76CrossRefPubMed
7.
Zurück zum Zitat Sheng Ding F, Li Kai W, Sidney M, Hecht J (1993) Inhibitors of DNA topoisomerase I isolated from the roots of Zanthoxylum nitidum. Org Chem 58:5025–5027CrossRef Sheng Ding F, Li Kai W, Sidney M, Hecht J (1993) Inhibitors of DNA topoisomerase I isolated from the roots of Zanthoxylum nitidum. Org Chem 58:5025–5027CrossRef
8.
Zurück zum Zitat Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME, Perfect JR (1999) Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother 43:2862–2868PubMed Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME, Perfect JR (1999) Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother 43:2862–2868PubMed
9.
Zurück zum Zitat Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58CrossRefPubMed Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58CrossRefPubMed
10.
Zurück zum Zitat Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654CrossRefPubMed Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654CrossRefPubMed
11.
Zurück zum Zitat Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302CrossRefPubMed Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302CrossRefPubMed
12.
Zurück zum Zitat Deeley RG, Cole SP (1997) Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8:193–204CrossRefPubMed Deeley RG, Cole SP (1997) Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8:193–204CrossRefPubMed
13.
Zurück zum Zitat Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931–959CrossRefPubMed Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931–959CrossRefPubMed
14.
Zurück zum Zitat Sarkadi B, Müller M, Holló Z (1996) The multidrug transporters–proteins of an ancient immune system. Immunol Lett 54:215–219CrossRefPubMed Sarkadi B, Müller M, Holló Z (1996) The multidrug transporters–proteins of an ancient immune system. Immunol Lett 54:215–219CrossRefPubMed
15.
Zurück zum Zitat Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512CrossRefPubMed Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512CrossRefPubMed
16.
Zurück zum Zitat Iwasaki H, Okabe T, Takara K, Toda T, Shimatani M, Oku H (2009) Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam. Cancer Chemother Pharmacol. doi:10.1007/s00280-009-1077-7 Iwasaki H, Okabe T, Takara K, Toda T, Shimatani M, Oku H (2009) Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam. Cancer Chemother Pharmacol. doi:10.​1007/​s00280-009-1077-7
17.
Zurück zum Zitat Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S (2001) Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280:1216–1223CrossRefPubMed Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S (2001) Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280:1216–1223CrossRefPubMed
18.
Zurück zum Zitat Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE (1999) Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59:5938–5946PubMed Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE (1999) Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59:5938–5946PubMed
19.
Zurück zum Zitat Iwasaki H, Oku H, Takara R, Miyahira H, Hanashiro K, Yoshida Y, Kamada Y, Toyokawa T, Takara K, Inafuku M (2006) The tumor specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam. Cancer Chemother Pharmacol 58(4):451–459 (Epub 2006 Feb 8)CrossRefPubMed Iwasaki H, Oku H, Takara R, Miyahira H, Hanashiro K, Yoshida Y, Kamada Y, Toyokawa T, Takara K, Inafuku M (2006) The tumor specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam. Cancer Chemother Pharmacol 58(4):451–459 (Epub 2006 Feb 8)CrossRefPubMed
20.
Zurück zum Zitat Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347–351CrossRefPubMed Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347–351CrossRefPubMed
21.
Zurück zum Zitat Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336–345CrossRefPubMed Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336–345CrossRefPubMed
22.
Zurück zum Zitat Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352–355CrossRefPubMed Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352–355CrossRefPubMed
23.
Zurück zum Zitat Marcil M, Brooks-wilson A, Clee SM et al (1999) Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354:1341–1346CrossRefPubMed Marcil M, Brooks-wilson A, Clee SM et al (1999) Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354:1341–1346CrossRefPubMed
24.
Zurück zum Zitat Marilyn MS, Angela AL, Tsai-Kun L, Hong-Yan W, Shyamal DD, Yong M, Eric HR, Edmond JL, Darshan M, Leroy FL (1998) Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells. Biochem Pharmacol 56:1157–1166CrossRef Marilyn MS, Angela AL, Tsai-Kun L, Hong-Yan W, Shyamal DD, Yong M, Eric HR, Edmond JL, Darshan M, Leroy FL (1998) Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells. Biochem Pharmacol 56:1157–1166CrossRef
25.
Zurück zum Zitat Kielar D, Dietmaier W, Langmann T, Aslanidis C, Probst M, Naruszewicz M, Schmitz G (2001) Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin Chem 47:2089–2097PubMed Kielar D, Dietmaier W, Langmann T, Aslanidis C, Probst M, Naruszewicz M, Schmitz G (2001) Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin Chem 47:2089–2097PubMed
26.
Zurück zum Zitat Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G (2003) Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49:230–238CrossRefPubMed Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G (2003) Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49:230–238CrossRefPubMed
Metadaten
Titel
Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine
verfasst von
Hironori Iwasaki
Takafumi Okabe
Kensaku Takara
Yasuhiko Yoshida
Kaoru Hanashiro
Hirosuke Oku
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1247-7

Weitere Artikel der Ausgabe 5/2010

Cancer Chemotherapy and Pharmacology 5/2010 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.